9th Jul 2021 18:06
(Alliance News) - Johnson & Johnson on Friday announced that ustekinumab, a treatment for ulcerative colitis, saw a 55% rate of remission after a Phase 3 study.
The New Jersey, US-based pharmaceutical major announced new three-year data from the long-term extension of the Stelara drug, or ustekinumab, Phase 3 UNIFI study.
"The data demonstrated the majority, or 55%, of adult patients with moderately to severely active ulcerative colitis who initially responded to treatment with Stelara sustained symptomatic remission rates at nearly three years," the company noted.
Seperately, PureTech Health PLC, a Boston, Massachusetts-based biotherapeutics firm, announced a collaboration between Vor Biopharma and Johnson & Johnson subsidiary Janssen Biotech Inc. PureTech owns 8.6% of Vor.
The collaboration is to develop engineered hematopoietic stem cell transplants combined with a bi-specific antibody therapy for acute myeloid leukemia.
"We are thrilled to enter into this collaboration with Janssen as we continue to explore our platform's potential to pair with a broad spectrum of targeted therapy modalities for the treatment of patients with blood cancer," said Vor Chief Scientific Officer Tirtha Chakraborty.
Johnson shares were up 0.4% at USD169.76 each in New York, while PureTech closed 0.3% higher at 341.50 pence in London.
By Greg Roxburgh; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech